Bio-Rad sees FY25 currency neutral revenue growth 1.5%-3.5%
Bio-Rad (BIO) is providing its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue ...
Bio-Rad Labs stock down 4% as Q4 revenue and guidance miss expectations
HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst ...
Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts
Bio-Rad Laboratories Inc (NYSE:BIO). reported its fourth-quarter 2024 earnings, revealing a slight miss on revenue expectations, with net sales of $668 million compared to a forecast of $681.29 ...